Skip to content

Pcrit and TPP for Risk Stratification in Patients with Sepsis

The Roles of Critical Closing Pressure and Tissue Perfusion Pressure in Risk Stratification for Patients with Sepsis

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06657196
Enrollment
6769
Registered
2024-10-24
Start date
2024-03-01
Completion date
2024-08-30
Last updated
2025-03-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Keywords

sepsis, critical closing pressure, tissue perfusion pressure, risk stratification

Brief summary

The goal of this observational study is to learn about the roles of critical closing pressure and tissue perfusion pressure in monitoring hemodynamic status, evaluating organ damage, and predicting mortality risk in patients with sepsis. The main question it aims to answer is: • Whether increases in critical closing pressure or tissue perfusion pressure are associated with a reduced risk of poor prognosis? Within the 24 hours following the diagnosis of sepsis, patients will be categorized into four groups based on their 24-hour mean critical closing pressure (Pcc) and tissue perfusion pressure (TPP) estimated from the hourly hemodynamic data within 24 hours. Outcomes will then be compared across these different groups. The study has been approved by the Medical Ethics Committee of Peking Union Medical College Hospital (K24C1937 and K25C0792).

Detailed description

To validate the reliability of mean Pcc estimated in the primary analysis, we prospectively collected hemodynamic data over a 24-h period from adult ICU patients with invasive arterial monitoring. Two methods were employed to estimate the mean Pcc for reliability validation. Based on the results of preliminary experiment, the sample size calculation showed that at least 12 individuals were needed for reliability validation.

Interventions

OTHERNo Intervention: Observational Cohort

No intervention.

Sponsors

Fu Xing Hospital, Capital Medical University
CollaboratorOTHER
West China Hospital
CollaboratorOTHER
First Hospital of China Medical University
CollaboratorOTHER
Shanghai Zhongshan Hospital
CollaboratorOTHER
The First Hospital of Jilin University
CollaboratorOTHER
China-Japan Friendship Hospital
CollaboratorOTHER
Beijing Friendship Hospital of Captial Medical University (Beijing)
CollaboratorUNKNOWN
Beijing Chao Yang Hospital
CollaboratorOTHER
General Hospital of Ningxia Medical University
CollaboratorOTHER
Xiangya Hospital of Central South University
CollaboratorOTHER
Beijing Tongren Hospital
CollaboratorOTHER
Peking University Third Hospital
CollaboratorOTHER
Xuanwu Hospital, Beijing
CollaboratorOTHER
Beijing Tiantan Hospital
CollaboratorOTHER
Guangdong Provincial People's Hospital
CollaboratorUNKNOWN
Peking Union Medical College Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years; * Sepsis was diagnosed according to Sepsis 3.0 criteria; * ICU stay exceeding 24 hours after enrollment; * Undergoing continuous monitoring of vital signs.

Exclusion criteria

* Significant absence of blood pressure and heart rate data within 24 hours of enrollment; * Pregnancy or breastfeeding; * brain death.

Design outcomes

Primary

MeasureTime frame
ICU mortalityFrom the date of trial enrollment until the date of discharge from ICU or date of death from any cause, whichever came first, assessed up to 6 months

Secondary

MeasureTime frame
In-hospital mortalityFrom the date of trial enrollment until the date of discharge from hospital or date of death from any cause, whichever came first, assessed up to 6 months
Incidence of acute kidney injury within 7 days of enrollmentFrom enrollment to 7 days post-enrollment or death
Incidence of acute kidney injury within 48 hours of enrollmentFrom enrollment to 48 hours post-enrollment or death
The maximum vasoactive inotropic scoreFrom enrollment to 24 hours after enrollment or death

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026